Diagnostic Innovation Reimagined
Unlocking earlier, more accurate disease detection and monitoring through next-generation sequencing.
Unlocking earlier, more accurate disease detection and monitoring through next-generation sequencing.
We identify the most urgent gaps in healthcare—areas our technologies are uniquely positioned to deliver transformative solutions.
We develop precision genomic and epigenomic tools through rigorous R&D—combining scientific innovation with impactful clinical relevance.
We optimize every solution for reliability, robustness, and throughput—accelerating the path from proof of concept to clinical and commercial readiness.
We launch each solution with clear paths to adoption—leveraging the most effective clinical, commercial, and strategic channels to maximize impact.
Our pipeline emphasizes clinically actionable biomarkers, scalable assay design, and a clear path to regulatory approval.
Neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS are often diagnosed too late for meaningful intervention. Resonant is developing blood tests for earlier detection and personalized care by identifying DNA biomarkers of dying neurons through cell-of-origin sequencing.
In collaboration with BYU and the University of Kansas ADRC, this approach is being validated in a 12-year longitudinal study of over 700 individuals.
